Astellas Pharma and Seagen have reported positive topline data from the Phase Ib/II EV-103 clinical trial (KEYNOTE-869) Cohort K of Padcev (enfortumab vedotin-ejfv) plus Keytruda (pembrolizumab) as first-line therapy for unresectable locally advanced or metastatic urothelial cancer (la/mUC) patients. 

A randomised cohort, EV-103 Cohort K is analysing enfortumab vedotin alone or along with pembrolizumab as first-line therapy for unresectable la/mUC patients, ineligible for cisplatin-based chemotherapy. 

According to the trial findings from this cohort, the combination therapy offered a confirmed objective response rate (ORR) per blinded independent central review (BICR) of 64.5%, the primary endpoint. 

Astellas noted that the median duration of response (DOR) per BICR was not attained. 

Rash maculo-papular, anaemia, lipase increased and urinary tract infection among others were the most commonly reported treatment-emergent adverse events Grade 3 or greater reported in over 5% of trial subjects. 

These results are generally in line with priorly reported efficacy and safety data from the EV-103 dose-escalation cohort and expansion Cohort A.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Astellas Development Therapeutic Areas senior vice-president and head Ahsan Arozullah said: “Approximately half of patients with advanced urothelial carcinoma are ineligible for cisplatin-based chemotherapy. 

“We intend to discuss Cohort K results with regulatory authorities as we seek to develop a new first-line treatment combination for these patients.”

Keytruda is an anti-PD-1 therapy of Merck.

Currently, Astellas, Seagen and Merck are analysing enfortumab vedotin plus pembrolizumab as part of a partnership, which includes three Phase III trials.

In May last year, Astellas and Seagen reported data from EV-201 and EV-103 trials where Padcev offered durable responses in locally advanced or metastatic urothelial cancer patients.